OncoMatch/Clinical Trials/NCT06438250

68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies

Is NCT06438250 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies 68Ga-JH04 for malignant neoplasm.

Early Phase 1RecruitingFirst Affiliated Hospital of Fujian Medical UniversityNCT06438250Data as of Jun 2026Location: China

Treatment: 68Ga-JH04 — 68Ga-JH04 is a novel radiotracer targeting fibroblast activation protein (FAP). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH04 in patients with different types of cancer.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

68Ga-JH04

Cancer type

Tumor Agnostic

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06438250 currently recruiting?

Yes, this trial is currently recruiting patients.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify